1. Home
  2. TRGP vs ARGX Comparison

TRGP vs ARGX Comparison

Compare TRGP & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Targa Resources Inc.

TRGP

Targa Resources Inc.

HOLD

Current Price

$261.18

Market Cap

57.7B

Sector

Utilities

ML Signal

HOLD

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$878.23

Market Cap

58.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRGP
ARGX
Founded
2005
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Natural Gas Distribution
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
57.7B
58.4B
IPO Year
2010
2017

Fundamental Metrics

Financial Performance
Metric
TRGP
ARGX
Price
$261.18
$878.23
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
19
Target Price
$257.29
$1,008.56
AVG Volume (30 Days)
1.1M
270.9K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
2.00%
N/A
EPS Growth
47.91
N/A
EPS
5.75
N/A
Revenue
$17,028,300,000.00
N/A
Revenue This Year
$30.33
$44.39
Revenue Next Year
$6.55
$20.84
P/E Ratio
$44.67
$33.69
Revenue Growth
3.95
N/A
52 Week Low
$144.14
$636.10
52 Week High
$291.04
$953.58

Technical Indicators

Market Signals
Indicator
TRGP
ARGX
Relative Strength Index (RSI) 41.71 50.36
Support Level $254.27 $823.21
Resistance Level $261.95 $881.89
Average True Range (ATR) 7.44 26.03
MACD -1.98 -0.85
Stochastic Oscillator 10.29 43.00

Price Performance

Historical Comparison
TRGP
ARGX

About TRGP Targa Resources Inc.

Targa Resources Corp is a midstream firm that mainly operates gathering and processing assets with substantial positions in the Permian, Stack, Scoop, and Bakken plays. It has fractionation capacity at Mont Belvieu and operates a liquefied petroleum gas export terminal. The Grand Prix natural gas liquids pipeline is another important asset. It has two operating segments: Gathering and Processing, and, Logistics and Transportation (also referred to as the Downstream Business).

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: